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In, mukivariateanalyses, FFS patientswere more likelyto undergoan-
giography(Odds ratio= 1.3 ci 1.1–1.6), butthere was no differencein the
use of revascularization.We concludethat the processof care is aimilarin
FFS and managedesre patientswithUAP,althoughFFS patientsare more
likely to undergo angiography.
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New therapieshave complexeconomic consaquencea. Consider the case
of an effective therapy to prevant restenosis after PTCA. Assume the initial
provider Coatis $12,000& restenosis (R) causes 20% repeat PTCAS,yield-
ing $2400 followup costs, or $14,400 total. Assume therapy decreasing R
50% costs $1000. Initial cost becomes $13,000 & followup $1300, a $100
savings total. Assume fee for service (FFS) providare charga cost +10%.
This describes a model of cost of R, varying in impact on provider & payer
depending on the type of reimbursement. (table, signs:+ cost, - savings).
Providers Pavers
Initial 6 Months initial 6 Months
Fee for Servica -$100 +$90 +$1100 -$1200
Packsgs Prica +$600 +$200 o -$1200
Capifsted +$1100 –$900 o 0
ReatenoaisPrevented
0.0 0.2 0.4 O.e 0.8 1.0
Under FFS, the payer takes the rick and provider consequences are
minimal. The aituation is reversed with cavitation.WithpackagePricin9, the
provider loses duetocost of therapy & Ieaaprocedures while the payer gains.
Sensitivity analyeis was used to further explore the model (see figure); in this
example under FFS, as therapy improved from no restenosis preventad
to 100% prevented, the payer savingsincreaaadfrom Oto $2400. A new
therapy may have considerable economic consequences, varying with time
& provider vs payer perspective.
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The mechanisms of PTCA in reetenosed etentad segments is incompletely
understood. Therefore, 24 patients with a > 50% diameter stenosis at six-
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month follow up (F-UP) were studied by intravascular ultrasound (IVUS,
30 MHz mechanical cathetera) and quantitative angiogrephy (QCA) after the
initial PTCA1,after stent implantation (Palmaz-Schatz, PS), at FU-P,and after
PTCA2 in reetenoeadstents. Thirty-one PS atents were implanted with IVUS
guidancein24 coronarylesions.Balloondiameterduringstent implantation
was 3.34 + 0.4 mm, and pressure 16 + 2 atm. Acute Iuminal area gain due
to stenting after PTCA was 4 mm2.At F-UP,minimal Iuminal diameter (QCA)
wae 1,3 * 0.5 mm. Stent area was unchanged (7.6 + 2 mm2 vs. 8 + 2.1
mmz at F.up). PTCAZ in the restenotic segments was performed with 11.1
+ 4.4 atm. Balloon size was unchanged compared with stent deployment.
Vessel area after PTCA2 increased from 19 & 5 mti to 21 + 7 mm2 and
stant area from 8 + 2.1 mm2to 9 + 2.5 mm2 (NS). The final lumen area was
significantly smaller compared to the acute procedure.
Conclusion: Intimal hyperplasia is the main cause for atent restenosis in
PS stents. PTCA2 resulted in only minor vessel and PS remodeling without
achieving the initial lumen diameters. This finding underlines the potential
role of debulking devices for treatment of in-stent restenosis.
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Coronary stenting reducaa reetenoais in lesions with early deterioration (>
0.3 mm) in minimal Iuminal diameter (MLD) occurring within the fimt 24,hs
after suceeesfulPTCA (early loss). Lesions with no early loss after eucceseful
PTCA have a low restenoaia rate. This study was deaignad to compare im-
mediate results and restenosis rate of lesions treated with coronary stenting
vs. those treatad with optimal PTCA (good immediate result and no early
loss at 30 minutes post-PTCA angiography). From December of 1995 to July
of 1996116 patients were randomized to stent (n = 57) or PTCA (n = 59).
Primary success was achieved in all patients in the PTCA and in the stent
groups; 13.5% of the PTCA group patients cross over to stent due to sub-
optimal results or early lose. Immediate quantitative coronary angiographic
results follow:
PTCA Stent D
Reference Diameter 2.S k 0.6 2.9 + 0.6 na
MLD post-lntewention 2,2* 0,4 2.8 * 0.6 <0,001
MLD 30 minpost-PTCA 2.2 + 0,5 -
Acute Gain 1.4 1.9 < .02
Stenoaiapeat (%) 17* 10 11 k 10 <0,01
Conclusion.’1)Coronary stenting achieves greater acute gain than opti-
mal PTCA. 2) Angiographic restenosis data will be available at the time of
presentation.
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The angiotensin converting enzyme (ACE) l/D polymorphism is of uncertain
aignifieartce in reetenosie after PTCA (R). From Dee. ’93 to Dec. ’95, 115
patients (p) (101 men, age61 + 9 y) were treatad with a first, elective, aingle-
veaael eoronaty Palmaz-Schafz stenting (CS) (130 etente in 115 lesions,
deployed at 14-20 atm with a balloon-vessel ratio = 1). P with ID diabetes,
aorto-ostial lesions, total occlusion >2 w&eks, leaion longer than 30 mm
DID (3S p) l/D (49 p) 1/1(26 p) p vslue (*)
D-ref (mm)
Ssfore PTCA 2.97 d 0.41 2,94 + 0,51 3.10 * 0.50 NS
After CS 3.15 * 0.36 3.14 * 0.39 3.29 + 0.67 NS
Follow-uP 2.94 + 0.44 2,S5 + 0,51 2,97 + 0.64 NS
MLD (mm)
Before PTCA 0.72 k 0.44 0.6S + 0.42 0.s3 * 0.54 FE
After CS 2.72 + 0.3S 2.67 & 0.35 2,85 + 0,65 NS
FOIIW-UP 1.s4 i 0.s2 1.ss * 0.s4 2,32 + 0,51 <0.05
“6DS
Safore PTCA 74* 14 74* 14 72& 13 NS
Aflar CS 15 i 7.7 15* S.1 13 h 6.S NS
Follow-uP 3S & 25 32+ 1S 26& 10 <0.05
% DS ? 50”A 12/36 (31”A) 6/49 (12%) 0/26 <0.C4XM
